An early phase II study of etoposide (VP-16) in advanced gastric cancer

Japanese Journal of Clinical Oncology

Volumn 26, Issue 1, 1996, Pages 36-41

  Yamao, Takekazu ^a   Shimada, Yasuhiro ^a   Ohtsu, Atsushi ^b   Hosokawa, Koichi ^a   Shirao, Kuniaki ^a   Kondo, Hitoshi ^a   Fukuda, Haruhiko ^a   Saito, Daizo ^a   Yoshida, Shigeaki ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemotherapy; Early phase II study; Etoposide (VP 16); Gastric cancer; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE;

ADENOCARCINOMA; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLLOID CARCINOMA; DRUG ADMINISTRATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; SIGNET RING CARCINOMA; STOMACH TUMOR;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SIGNET RING CELL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 0030075750     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jjco.a023176     Document Type: Article

References (32)

1. Watanabe S, Tsugane S, Ohno Y: Prediction of the gastric cancer mortality in 2000 in Japan. Jpn J Cancer Res 79: 439-444, 1988
2. Moertel CG: Chemotherapy of gastrointestinal cancer. In Recent Advances in Cancer Treatment, Tagnon HJ, Staquest MJ eds, Raven Press, New York. p311-323, 1977
3. Miyamoto K, Yoshida S, Saito D, Shimada Y, Tajiri H, Yamaguchi H, Ohkura H, Yoshio M, Yoshida T, Okazaki N, Yoshimori M, Hijikata A: Pilot phase II study of cisdiaminedichloroplatinum (II) against metastatic gastric cancers. Jpn J Clin Oncol 20: 169-176, 1990
4. Bender RA, Hamel E, Hande KR: Plant alkaloids in cancer chemotherapy. In Cancer Chemotherapy Principles and Practice, Chabner BA, Collins JM, eds, Lippincott, Philadelphia, PA. p262-270, 1990
5. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE: Etoposide (VP-16-213); current status of an active anticancer drug. N Engl J Med 312: 692-700, 1985
6. Belani CP, Doyle LA, Aisner J: Etoposide - current status and further perspectives in the management of malignant neoplasms. Cancer Chemother Pharmacol 34 (Suppl): 118-126, 1994
7. Preusser P, Wilke H, Achterrath W, Fink U, Meyer J, Scnmitz-Hübner U, Bünte H: Advanced gastric carcinoma - a phase II study with etoposide (E), adriamycin (A), and split course cisplatin (P) = EAP. Proc Am Soc Clin Oncol 6: 75, 1987
8. Kelsen DP, Magill GB, Cheng E, Dukeman M, Sordillo P, Heelan R, Yagoda A: Phase II trial of etoposide in adenocarcinoma of the upper gastrointestinal tract. Cancer Treat Rep 67: 509-510, 1983
9. Simon R: How large should a phase II trial of a new drug be? Cancer Treal Rep 71: 1079-1085, 1987
10. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment, Geneva. 1979
11. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma, 1st English ed, Kanehara, Tokyo. 1995
12. Ohtsu A, Yoshida S, Saito D, Shimada Y, Miyamoto K, Fujii T, Yoshino M, Yoshimori M: An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 21: 120-124, 1991
13. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K, Kurihara M: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 30: 2091-2093, 1994
14. Kimura K, Yamada K, Niitani H: A phase I clinical study of NK-171 (etoposide). Gan To Kagakuryoho 12: 851-856, 1985 (in Japanese)
15. Lock RB, Hill BT: Differential patterns of antitumor drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumor cell lines. Int J Cancer 42: 373-381, 1988
16. Wallner J, Depisch D, Gsur A, Götzl M, Haider K, Pirker R: MDRI gene expression and its clinical relevance in primary gastric carcinomas. Cancer 71: 667-671, 1993
17. Potmesil M, Hsiang YH, Liu LF, Bank B, Grossberg H, Kirschenbaum S, Forlenza TJ, Penziner A, Kanganis D, Knowles D, Traganos F, Silber R: Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48: 3537-3543, 1988
18. Danks MK, Yalowich JC, Beck WT: Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297-1301, 1987
19. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Buente H: Phase II study with combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317, 1989
20. Lerner A, Gonin R, Steele GD Jr, Mayer RJ: Etoposide, doxorubicine, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 10: 536-540, 1992
21. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapmon D, Heelan R, Lightdale C, Vinciguerra V, Brennan M: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541-548, 1992
22. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333-1340, 1989
23. Miller JC, Einhorn LH: Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17 (Suppl): 36-39, 1990
24. Hainsworth JD, Johnson DH, Frazier SR, Greco FA: Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 26: 818-821, 1990
25. Joel SP, Slevin ML: Schedule-dependent topoisomerase II-inhibiting drugs. Cancer Chemother Pharmacol 34 (Suppl): 584-588, 1993
26. Greco FA, Hainsworth JD: Prolonged administration of low-daily-dose etoposide: a superior dosing schedule? Cancer Chemother Pharmacol 34 (Suppl): 101-104, 1994
27. Ajani JA, Dumas P: Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report. Semin Oncol 19 (Suppl 14): 45-47, 1992
28. Creaven PJ, Allen LM: EPEG, a new antineopiastic epipodophyllotoxin. Clin Pharmacol Ther 18: 221-226, 1975
29. Strife RJ, Jardine I, Colvin M: Analysis of the anticancer drug VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography. J Chromatogr 182: 211-220, 1980
30. Arnold AM, Dodson M, Renwick A, Whitehouse JMA: Pharmacokinetics of VP 16-213 using a new HPLC assay. Cancer Chemother Pharmacol 5 (Suppl): 2, 1980
31. Miller AA, Stewart CF, Tolly EA: Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemother Pharmacol 25: 361-366, 1990
32. Stewart CF, Arbuck SG, Fleming RA, Evans WE: Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 50: 385-393, 1991